{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-22-000033","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.063035+00:00","generated_at":"2026-06-26T00:50:28.549990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Allogene reports Q1 net loss $79.9M, cash $733M; plans pivotal ALLO-501A trial mid-2022","bullets":["Net loss $79.9M ($0.56/sh); R&D $60.2M, G&A $19.9M; cash $733.1M at March 31, 2022.","Pivotal Phase 2 ALPHA2 trial of ALLO-501A in R/R large B cell lymphoma to start mid-2022 using CF1 product.","FDA granted Orphan Drug Designation for ALLO-605 (TurboCAR) for multiple myeloma; Fast Track for ALLO-316 for RCC.","Full-year 2022 GAAP OpEx guided at $360-390M, including $90-100M stock-based compensation.","Cell Forge 1 operational; projected annual capacity of ~20,000 AlloCAR T doses at scale."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-22-000033","json":"https://secwatch.observer/filing/0001737287-22-000033.json","markdown":"https://secwatch.observer/filing/0001737287-22-000033.md","text":"https://secwatch.observer/filing/0001737287-22-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000033/0001737287-22-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000033/allo-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:50:28.549990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}